Scroll To Top
Search by Speciality

Targeting PI3K/mTOR by AACR

The Westin Boston Waterfront * | Boston, USA
From 850 to 1285 USD
Event Preview
This event
is Finished
Title: Targeting PI3K/mTOR by AACR
Specialty: Internal Medicine
Dates: From Nov, 30, 2018 to Dec, 30, 2018
Location: Boston, USA
Type: Course
Registration Cost: From 850 to 1285 USD
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
  • Scientific Programm
  • Online registration
  • Exhibition floorplans
  • Sponsorship &
    Exhibition consensus
  • Virtual Booths
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for Boston, Usa.
General Info
Event Venue:

The Westin Boston Waterfront *

Boston, USA Visit the Venue to read more


The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this live activity for a maximum of 17.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Friday, January 11, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on this website and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Statement of Educational Need, Target Audience, and Learning Objectives

Genetic events leading to aberrant activation of the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathway are among the most frequently occurring alterations in human cancers.  In normal cells, this pathway responds to growth factors, cytokines, and hormones, such as insulin, and promotes cell growth, proliferation, survival, and metabolism through a variety of downstream targets.  Oncogenic mutations in cancer cells activate this pathway in a manner that disconnects its control of these cellular processes from normal growth signals, leading to constitutive activation of the pathway.  Cancer genome sequencing efforts combined with numerous preclinical and clinical studies have highlighted the importance of this pathway in cancer development and progression.

From molecular and cell biologic studies, it has become increasingly clear that PI3K is not part of a linear pathway but rather a key component of a broader network of signaling pathways, with intimate connections to the mechanistic target of rapamycin (mTOR) and Ras pathways, among others.  PI3K and mTOR are particularly intertwined, with the mTOR protein complexes (mTORC1 and mTORC2), acting as both downstream effectors and central regulators of the pathway.  Furthermore, while PI3K is predominantly a lipid kinase and mTOR is a protein kinase, these two proteins are structurally related to each other, such that chemical inhibitors can often directly inhibit the activity of both proteins. mTOR signaling is elevated in the majority of human cancers, and this occurs, in part, through oncogenic activation of the PI3K pathway.  The focus of this meeting is on understanding and targeting the PI3K-mTOR network in cancer.

Concerned Audience:
  • Medical_Professionals
  • Medical_students
  • Nurses
Event Overview
Welcome message:
The PI3K-mTOR signaling pathway is one of the most frequently dysregulated signaling cascades in cancer. This AACR Special Conference will highlight recent progress in understanding the molecular wiring of the PI3K-mTOR signaling network and its activation in cancer, the major downstream functions contributing to cancer pathology, and therapeutic strategies for targeting the network. This program will span from basic science to the most recent clinical advances, thus providing a forum for active discussion and collaboration among all sectors in the cancer workforce. The conference will cover topics including the biology of the PI3K/mTOR pathway, translational control in cancer, autophagy, immunology, structural biology, and the latest updates from clinical trials.

Lewis C. Cantley, Meyer Cancer Center, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York

David M. Sabatini, MIT Whitehead Institute for Biomedical Research, Cambridge, Massachusetts

Jean J. Zhao, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Registration Needs updating Register Now


Registration Cost
Early Registration

Late Registration From: 2018-08-09 To: 0--
On site Registration
AACR Members
Non Members

Group Registrations:

Group registrations not allowed

Accompanying Persons:

Accompanying persons not allowed

Registration Documents:
Letter of invitation:
We don’t provide letter of invitation
Letter of confirmation:
We don’t provide Letter of Confirmation
Proof of professional / educational status:
We don’t need Proof of professional/educational status
Online Abstract Submission:

We don’t accept Online Abstracts


The Westin Boston Waterfront

425 Summer St,

Boston, Massachusetts, United States Of America

Scientific Content Up to Date
Submission Info
Sponsors Exhibitors
General Info

Contact No.: 215-440-9300,617-227-0051


Organising Agency

Contact No.: 215-440-9300,617-227-0051


Event map
Revelant Events